Sage Therapeutics (SAGE) Neutral Rating Reaffirmed at HC Wainwright

HC Wainwright maintained a neutral rating on the stock Sage Therapeutics (NASDAQ:SAGE – Free Report) in a research note published on Tuesday morning, Benzinga reports. The brokerage currently has a price target of $25.00 on the biopharmaceutical company’s shares.

Several other brokerages have also recently commented on SAGE. Canaccord Genuity Group lowered their price objective for Sage Therapeutics from $21.00 to $17.00 and set a maintain rating for the company in a research report on Friday, April 26. Oppenheimer lowered their price objective for Sage Therapeutics from $25.00 to $17.00 and set a market perform rating for the company in a report on Thursday, April 18. Baird RW raised Sage Therapeutics to a maintain rating in a report on Wednesday, May 29. TD Cowen lowered their price objective for Sage Therapeutics from $30.00 to $16.00 and set a buy rating for the company in a report on Thursday, April 18. Finally, Truist Financial lowered their price objective for Sage Therapeutics from $22.00 to $18.00 and set a Hold rating for the company in a report on Friday, April 26. Two research analysts rated the stock with a Sell rating, sixteen have issued a Hold rating, and three have assigned a Buy rating. Based on data from MarketBeat.com, Sage Therapeutics currently has an average rating of Hold and a consensus price target of $34.80.

See our latest analysis for Sage Therapeutics

Sage Therapeutics shares fall 1.9%

Shares of Sage Therapeutics opened at $10.82 on Tuesday. The company has a market cap of $651.15 million, a P/E ratio of -1.29 and a beta of 0.90. Sage Therapeutics has a 52-week low of $9.76 and a 52-week high of $49.74. The company’s 50 day moving average price is $11.78 and its 200 day moving average price is $18.07.

Sage Therapeutics (NASDAQ:SAGE – Get Free Report) last released its quarterly financial results on Thursday, April 25. The biopharmaceutical company reported (1.80) earnings per share for the quarter, which was (0.17) lower than the analyst consensus of (1.63). The company had revenue of $7.90 million for the quarter, compared to analyst expectations of $5.26 million. Sage Therapeutics reported a negative net margin of 552.52% and a negative return on equity of 56.81%. The company’s revenue increased by 139.4% compared to the same quarter last year. During the same period last year, the company posted (2.46) earnings per share. Research analysts predict that Sage Therapeutics will post -6.48 earnings per share for the current year.

Institutional investors evaluate Sage Therapeutics

Several major investors have recently added to or reduced their holdings in SAGE. Wellington Management Group LLP increased its holdings in shares of Sage Therapeutics by 3.3% in the third quarter. Wellington Management Group LLP now owns 6,572,260 shares of the biopharmaceutical company’s stock worth $135,257,000 after purchasing an additional 208,630 shares during the period. Vanguard Group Inc. increased its holdings in shares of Sage Therapeutics by 8.1% in the first quarter. Vanguard Group Inc. now owns 5,751,373 shares of the biopharmaceutical company’s stock worth $107,781,000 after purchasing an additional 432,013 shares during the period. RTW Investments LP increased its holdings in shares of Sage Therapeutics by 0.9% in the fourth quarter. RTW Investments LP now owns 5,197,019 shares of the biopharmaceutical company’s stock worth $112,619,000 after purchasing an additional 47,537 shares during the period. Bellevue Group AG increased its holdings in shares of Sage Therapeutics by 27.1% in the first quarter. Bellevue Group AG now owns 4,465,544 shares of the biopharmaceutical company’s stock worth $83,684,000 after purchasing an additional 952,193 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Sage Therapeutics by 69.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 811,934 shares of the biopharmaceutical company’s stock worth $15,217,000 after purchasing an additional 333,805 shares in the last quarter. Hedge funds and other institutional investors own 99.22% of the company’s shares.

Sage Therapeutics Company Profile

(Download the free report)

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health therapeutics. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.

Featured Articles

Get daily news and reviews for Sage Therapeutics – Enter your email address below to receive a concise summary of the latest news and analyst ratings for Sage Therapeutics and related companies in MarketBeat.com’s FREE daily newsletter.